Forendo Pharma Oy
http://forendo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Forendo Pharma Oy
Organon Widens Business Development Lens To Maintain Women’s Health Focus
Organon has not strayed from its women’s health path, but is entering into earlier deals and considering technologies beyond therapeutics, while advocating increased investment in the field.
Finance Watch: Vertex Ventures, Chugai Each Raise New $200m VC Funds
Private Company Edition: Vertex Ventures (not Vertex Pharmaceuticals) closed its third fund, with $200m for life science and medical technologies, while Chugai’s $200m corporate VC fund will invest in drug discovery start-ups. Also, K36 closed a $70m series B round and Attovia launched with $60m.
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
A Guiding Hand For Biotech Start-Ups In Turbulent Times
Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Organon
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice